简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract：ADA is on target to extend its winning streak to three sessions. Updates from the telemedicine space in LatAm has delivered price support.
On Saturday, cardano (ADA) rose by 0.57%. Consolidating a 2.65% gain from Friday, ADA ended the session at $0.351.
Network updates provided ADA with rare support, with bullish sentiment from the broader market also contributing.
However, the technical indicators remain bearish, with ADA below the 50-day EMA to leave sub-$0.30 in play.
On Saturday, ADA rose by 0.57%. Following a 2.65% rally from Friday, ADA ended the day at $0.351. While avoiding a new 2022 low, ADA ended the session at sub-$0.40 for the twelfth consecutive session.
A mixed morning saw ADA fall to an early morning low of $0.343. Steering clear of the First Major Support Level (S1) at $0.336, ADA rose to a late morning high of $0.354. However, falling short of the First Major Resistance Level (R1) at $0.356, ADA fell back to sub-$0.350 before wrapping up the day at $0.351.
While FOMC member chatter and comments from US Treasury Secretary Janet Yellen continued delivering support, Cardano network updates provided rare support.
On Saturday, Citaldoc announced the first ADA transaction on its telemedicine platform.
Citaldoc made the announcement on Twitter, saying,
“We are getting emotional right now. First ADA transaction in our telemedicine platform.”
Citaldoc provided the details of the test transaction of 10,000 ADA, which had a transaction fee of just 0.17 ADA (0.0017%).
It was good news for the Cardano team and ADA holders. Post-Vasil hard fork weekly development updates have failed to impress. Citaldoc and the anticipated growth in the telemedicine space place Cardano in a position to grow in the Latin American market.
Citaldoc is a telemedicine platform that allows patients to make consultations and receive medical guidance with their reference doctor or with a specialist in the health area that is part of the Citaldoc network. The platform uses video call technology, text messaging, or both in a secure environment.
According to a recent Bloomberg piece,
“The global digital health market size is expected to reach $1.5 trillion by 2030.”
The report went on to say,
“Tele-healthcare segment dominated the global market in 2021 with a market revenue share of 37.6% due to increasing preference for remote patient monitoring services and a shortage of healthcare professionals.”
Saturdays news followed another disappointing Input Output HK (IOHK) weekly update.
On Friday, Input Output HK (IOHK) released the Cardano Weekly Development Report for October 21. Project numbers failed to impress, with an influx of projects yet to materialize.
According to the latest report,
103 projects launched on Cardano, up by one from the previous week.
1,122 projects are building on Cardano, up by two from the previous week.
Before the Vasil hard fork, the number of projects launched on Cardano had stood at 98, with 1,100 projects building on the Cardano network.
The growth in telemedicine provides opportunities for Cardano and others to see rapid adoption.
This morning, ADA was up 1.14% to $0.355. A bullish start to the day saw ADA rise from an early low of $0.350 to a high of $0.357 before easing back.
ADA briefly broke through the First Major Resistance Level (R1) at $0.356.
ADA needs to avoid the $0.349 pivot to break out from the First Major Resistance Level (R1) at $0.356 and target the Second Major Resistance Level (R2) at $0.360. However, ADA would need the support of the broader crypto market to break out from the morning high of $0.357.
In the case of an extended bullish session, ADA would likely test resistance at $0.365 but fall short of the Third Major Resistance Level (R3) at $0.371.
A fall through the pivot would bring the First Major Support Level (S1) at $0.345 into play. However, barring an extended sell-off, ADA should avoid sub-$0.340 and the Second Major Support Level at $0.338. The Third Major Support Level (S3) sits at $0.327.
This morning, the EMAs and the 4-hourly candlestick chart (below) sent a bearish signal.
ADA sat below the 50-day, currently at $0.360. The 50-day EMA eased back from the 100-day EMA, with the 100-day EMA falling back from the 200-day EMAs, delivering bearish signals.
A move through R1 ($0.356) would give the bulls a run at R2 ($0.360) and the 50-day EMA ($0.360). The 200-day EMA sits at $0.404. However, failure to move through the 50-day EMA ($0.360) would bring S1 ($0.345) into view.
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.
GmtFX has been flagged by Swiss regulators for operating without authorisation. WikiFX data shows no license, low safety scores, and elevated investor risk.
A close look at ZarVista's regulatory status shows major red flags that mark it as a high-risk broker for traders. This analysis goes beyond the company's marketing materials to examine the real substance of its licenses, business structure, and operating history. The main issues we will explore include its dependence on weak offshore regulation, a large number of serious user complaints, and worrying details about its corporate identity. It is also important to note that ZarVista previously operated under the name Zara FX, a detail that provides important background to its history. This article aims to deliver a complete, evidence-based breakdown of the ZarVista license framework and its real-world effects, helping traders understand the serious risks involved before investing.
Warning: Multibank Group faces multiple allegations of scams in Vietnam, the UAE, and Italy. Reports include blocked withdrawals, confiscated profits, and fraudulent practices. Stay vigilant and protect your funds.
When traders think about choosing a new broker, two main questions come up: Is ZarVista safe or a scam? And what are the common ZarVista complaints? These questions get to the heart of what matters most—keeping your capital safe. This article gives you a detailed look at ZarVista's reputation using public information, government records, and real experiences from people who used their services. Our research starts with an important fact that shapes this whole review. WikiFX, a website that checks brokers independently, gives ZarVista a trust score of only 2.07 out of 10. This very low rating comes with a clear warning: "Low score, please stay away!" The main reason for this low score is the large number of user complaints. This finding shows that ZarVista might be risky to use. To get the complete picture, we will look at the broker's government approval status, examine the specific complaints from users, check any positive reviews to be fair, and give you a final answer based on fact
WikiFXWikiFXWikiFXWikiFXWikiFXWikiFXWikiFXWikiFXWikiFXWikiFX
